Table 5 Prognostic factors for distant disease-free survival: multivariate analysis
|  | Model 1 (N = 570) |  | Model 2 (N = 575) |  |
|---|---|---|---|---|
| Â | HR (95 % CI) | p-valuea | HR (95 % CI) | p-valuea |
Age | ||||
  < 35 | 1 |  | 1 |  |
  ≥ 35 | 0.4 [0.1–2.1] | 0.344 | 0.4 [0.09–1.8] | 0.251 |
SBR Grade | ||||
 1–2 | 1 |  | NA |  |
 3 | 3.4 [1.5–7.6] | 0.0027 | NA |  |
Pathological tumor size | ||||
 pT1 | 1 |  | 1 |  |
 pT2 | 1.0 [0.5–2.0] | 0.932 | 1.0 [0.5–2.1] | 0.847 |
 pT3-T4 | 0.7 [0.09–5.3] | 0.733 | 0.7 [0.09–5.5] | 0.763 |
PVI | ||||
 No | 1 |  | 1 |  |
 Yes | 1.7 [0.8–3.6] | 0.155 | 1.5 [0.7–3.2] | 0.275 |
Hormone receptors | ||||
 Negative | 1 |  | NA |  |
 Positive | 0.9 [0.4–2.0] | 0.865 | NA |  |
HER2 | ||||
 Positive | 1 |  | NA |  |
 Negative | 0.7 [0.2–2.0] | 0.605 | NA |  |
IHC subtypes | ||||
 Luminal A | NA |  | 1 |  |
 Luminal B-HER2–negative | NA |  | 4.4 [1.7–11.5] | 0.0018 |
 Luminal B-HER2-positive | NA |  | 1.2 [0.2–5.9] | 0.775 |
 HER2 | NA |  | 2.8 [0.7–10.9] | 0.118 |
 Triple-negative | NA |  | 3.4 [1.3–8.7] | 0.0074 |